GlassScriptPhysician profile
Abdallah Abdallah
NPI 1841685773
$6,771.32
in general payments reported to CMS, 2019-2025
28 companies · $2,878 in 2025
The $2,878 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.36 · 2020: $44.24 · 2021: $598 · 2022: $859 · 2023: $1,025 · 2024: $1,342 · 2025: $2,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,960 · Travel and Lodging: $2,186 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.69 |
| Travel and Lodging | $2,186.14 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,984.04 | 2024-2025 | Overstitch Endoscopic Suturing System, Spyglass, Spyglass |
| Abbvie INC. | $1,066.49 | 2021-2025 | Skyrizi, Rinvoq |
| Olympus Corporation of The Americas | $731.64 | 2024 | Visiglide |
| Janssen Biotech, INC. | $670.86 | 2021-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $367.25 | 2021-2023 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $226.83 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Scientific Affairs, LLC | $208.89 | 2021-2023 | Stelara |
| Conmed Corporation | $196.20 | 2021 | |
| Medtronic, INC. | $193.52 | 2023-2025 | Manoscan, Endoflip |
| Apollo Endosurgery US INC | $118.95 | 2023 | Overstitch Endoscopic Suturing System |
| Madrigal Pharmaceuticals | $112.95 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $105.76 | 2023 | Terlivaz |
| Erbe USA INC | $100.00 | 2023-2024 | Erbe Vio3 |
| Intuitive Surgical, INC. | $92.61 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.80 | 2021-2025 | Xifaxan |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $63.50 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $62.09 | 2025 | Dupixent |
| Lucid Diagnostics INC. | $59.63 | 2024-2025 | |
| Pfizer INC. | $54.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $52.29 | 2023-2024 | Dificid |
| La Jolla Pharmaceutical Company | $41.71 | 2021 | |
| Celgene Corporation | $37.92 | 2022-2024 | Zeposia |
| Olympus America INC. | $37.39 | 2023-2025 | Endoclot Phs, Single Use Electrosurgical Knife Kd-655 |
| Intercept Pharmaceuticals, INC. | $32.87 | 2023-2025 | Ocaliva |
| Novo Nordisk INC | $26.42 | 2025 | Wegovy |
| Allergan, INC. | $26.38 | 2019-2020 | |
| Braintree Laboratories, INC. | $19.44 | 2025 | Suflave, Sutab |
| Astrazeneca Pharmaceuticals LP | $13.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdallah Abdallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.